Pfizer is betting on gene therapy via external R&D deals with Immusol, Myco, others.
"PFIZERGEN" WILL BE PFIZER BIOTECH R&D COLLABORATION NETWORK for genetic and biotechnology research: Pfizer has entered agreements with Immusol, AEA Technology, Oxford Asymmetry and Myco Pharmaceuticals for joint R&D and for technologies and resources that will enhance internal Pfizer research operations, Pfizer announced March 24.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth